VOR
Vor Biopharma Inc.
There isn't enough reported data to score VOR yet.
VOR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
VOR's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
VOR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.3x | $19.30 | -0.1% |
| Fair | 0.3x | $19.67 | +1.8% |
| Current | 0.3x | $19.32 | — |
| Expensive | 0.4x | $19.68 | +1.9% |
Historical ranges are pointers, not guarantees.
VOR's PE is 0.3x, but its earnings don't support one, so it isn't a reliable read right now.
VOR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect VOR's earnings to decline, with its revenue and profitability holding steady.
VOR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $56.23 | +$443.06 |
| Q2 2026 | -$63.95 | +$209.25 |
| Q1 2026 | -$313.99 | -$283.79 |
| Q4 2025 | -$314.08 | -$280.08 |
| Q3 2025 | -$386.83 | -$354.03 |
| Q2 2025 | -$273.20 | -$238.60 |
| Q1 2025 | -$30.20 | +$5.20 |
| Q4 2024 | -$34.00 | +$1.00 |
VOR has returned to profit: it earned $56.23 per share over the past year, after losing money the year before.
VOR Quarterly Revenue
VOR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$32.8M | +$21.1M |
| Q2 2026 | -$25.5M | +$9.8M |
| Q1 2026 | -$38.3M | -$7M |
| Q4 2025 | -$23.1M | +$1M |
| Q3 2025 | -$53.9M | -$30.6M |
| Q2 2025 | -$35.3M | -$13.5M |
| Q1 2025 | -$31.3M | -$718K |
| Q4 2024 | -$24.1M | +$2K |
VOR has burned cash in almost every quarter: −$120M over the past year, against −$145M the year before.
VOR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.9% | +5.4M shares |
| 1 year | +853% | +53.4M shares |
| 3 years | +1701% | +56.4M shares |
| 5 years | +5260% | +58.6M shares |
| Available history | +9675% | +59.1M shares |
VOR has 60M diluted shares, up 853% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
VOR Net Leverage
VOR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.2 | Neutral |
| Stochastic | 24.8 | Neutral |
VOR's weekly RSI is 50 (neutral) and its Stochastic is 25 (neutral).
VOR PE vs Healthcare Sector
VOR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.0 | 1.5% above |
| 20 week MA | $20.6 | 6.2% below |
| 50 week MA | $16.7 | 15% above |
| 100 week MA | $20.3 | 4.6% below |
| 200 week MA | $35.1 | 45% below |
VOR's trend is mixed: it's above two of its five weekly moving averages, and 45% below its 200-week average.
VOR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $750.0 | $263.2 | -65% |
| 2022 | $263.2 | $140.2 | -47% |
| 2023 | $140.2 | $45.0 | -68% |
| 2024 | $45.0 | $25.4 | -44% |
| 2025 | $25.4 | $14.7 | -42% |
| 2026 YTD | $14.7 | $19.3 | +31% |
VOR has finished every year since 2021 lower, and it's up 31% so far in 2026.